Combining personalized cancer vaccines with immune therapy for ovarian cancer
Project 2: Combined personal neoantigen-targeting cancer vaccines with immune checkpoint blockade for ovarian cancer
This study is exploring a new way to treat ovarian cancer by creating personalized vaccines that target specific changes in your tumor, and it will see how well these vaccines work when combined with regular chemotherapy to help your immune system fight the cancer better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10895324 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating ovarian cancer by combining personalized neoantigen-targeting vaccines with immune checkpoint blockade therapy. The study aims to identify specific mutated proteins in a patient's tumor that can stimulate a strong immune response against cancer cells. By using advanced computational tools, researchers will create tailored vaccines for patients and assess their effectiveness when used alongside standard chemotherapy. This innovative strategy seeks to enhance the immune system's ability to fight ovarian cancer more effectively than current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced ovarian cancer who have not responded adequately to standard chemotherapy.
Not a fit: Patients with early-stage ovarian cancer or those who have not been diagnosed with ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for ovarian cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar personalized vaccine approaches in other cancers, indicating potential for success in ovarian cancer as well.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Konstantinopoulos, Panagiotis — Dana-Farber Cancer Inst
- Study coordinator: Konstantinopoulos, Panagiotis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.